BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 25262704)

  • 61. A case of primary ovarian lymphoma in a child with high levels of CA125 and CA19-9.
    Koksal Y; Caliskan U; Ucar C; Reisli I
    J Pediatr Hematol Oncol; 2005 Nov; 27(11):594-5. PubMed ID: 16282889
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Serum CA 19-9 and CA 125 as a diagnostic marker in carcinoma of gallbladder.
    Bind MK; Mishra RR; Kumar V; Misra V; Singh PA
    Indian J Pathol Microbiol; 2021; 64(1):65-68. PubMed ID: 33433411
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [CA 125 expression in cervical and vaginal secretions in women in normal reproductive period].
    He SM; Xing FQ; Sui H; Wang YL; Mai XF; Luo ZQ; Chen XQ; Chen GH; Kong ZJ
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 Jan; 30(1):173-5. PubMed ID: 20118015
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Increased serum CA125 levels in plasma cell dyscrasias.
    Iwasaki T; Hamano T; Aizawa K; Kobayashi K; Kakishita E
    Acta Haematol; 1997; 98(2):104-8. PubMed ID: 9286307
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Cerebral infarcts associated with adenomyosis: a rare risk factor for stroke in middle-aged women: a case series.
    Yin X; Wu J; Song S; Zhang B; Chen Y
    BMC Neurol; 2018 Dec; 18(1):213. PubMed ID: 30567506
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Uterine adenomyotic cyst with markedly elevated serum CA19‑9 and CA125 levels: A case report.
    Zheng L; Shan L; Cai F
    Exp Ther Med; 2022 Nov; 24(5):665. PubMed ID: 36168421
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Factors associated with serum CA19-9 levels among healthy children: a cross-sectional study.
    Kawai S; Oba-Shinjo SM; Ito LS; Uno M; Marie SKN; Hamajima N
    BMC Clin Pathol; 2012 Dec; 12():23. PubMed ID: 23206543
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Carbohydrate antigen 125: a useful marker of congestion, fibrosis, and prognosis in heart failure with preserved ejection fraction.
    Menghoum N; Badii MC; Deltombe M; Lejeune S; Roy C; Vancraeynest D; Pasquet A; Gerber BL; Horman S; Gruson D; Beauloye C; Pouleur AC
    ESC Heart Fail; 2024 Jun; 11(3):1493-1505. PubMed ID: 38339764
    [TBL] [Abstract][Full Text] [Related]  

  • 69. An Observational Study of Factors affecting CA125 Levels in Premenopausal Women.
    Balachandran A; Nayak SR
    Adv Biomed Res; 2023; 12():235. PubMed ID: 38073732
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Factors associated with serum CA125 level in women without ovarian cancer in the United States: a population-based study.
    Hu X; Zhang J; Cao Y
    BMC Cancer; 2022 May; 22(1):544. PubMed ID: 35568827
    [TBL] [Abstract][Full Text] [Related]  

  • 71. CA125 is superior to CA19-9 in predicting the resectability of pancreatic cancer.
    Luo G; Xiao Z; Long J; Liu Z; Liu L; Liu C; Xu J; Ni Q; Yu X
    J Gastrointest Surg; 2013 Dec; 17(12):2092-8. PubMed ID: 24146342
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Ovarian tumor markers of presumed benign ovarian tumors].
    Lahlou N; Brun JL
    J Gynecol Obstet Biol Reprod (Paris); 2013 Dec; 42(8):752-9. PubMed ID: 24210243
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Dilution effect of serum CA125 and CA19-9 over a cutoff value, according to obesity.
    Kim JH; Park BR; Yang WJ
    Int J Biol Markers; 2015 Feb; 30(1):e122-6. PubMed ID: 25262704
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Effect of obesity-related plasma hemodilution on serum tumor marker concentration in women.
    Park M; Chang IH; Kang H; Han SS
    J Obstet Gynaecol Res; 2015 May; 41(5):784-9. PubMed ID: 25421332
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The diagnostic value of determination of serum GOLPH3 associated with CA125, CA19.9 in patients with ovarian cancer.
    Fan HY; Duan DM; Liu YF
    Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4039-4044. PubMed ID: 29028099
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The prognostic values of CA125, CA19.9, NSE, AND SCC for stage I NSCLC are limited.
    Ma S; Shen L; Qian N; Chen K
    Cancer Biomark; 2011-2012; 10(3-4):155-62. PubMed ID: 22674301
    [TBL] [Abstract][Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.